⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of CPTx and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
CPTx
↗Planegg, Germany
CPTx is a privately held German biotechnology company developing genetic medicines based on immune-quiet, programmable single-stranded DNA. Its current lead focus is non-viral, in vivo CAR-T therapy using ssDNA payloads delivered through targeted lipid nanoparticles, with the goal of enabling durable but tunable gene expression, repeat dosing, and potentially more accessible cell therapies than conventional ex vivo CAR-T. The company states that its platform can support multiple genes, duration-controlled expression, and applications across oncology, autoimmune disease, and other genetic-medicine indications. ([cptx.bio](https://cptx.bio/))
The company was founded in 2021 as a spinout of research led by Technical University of Munich scientist Hendrik Dietz and was previously registered under the name capsitec GmbH before adopting the CPTx name. CPTx maintains headquarters, laboratories, and manufacturing operations in Planegg/Munich, Germany, together with a U.S. office in South San Francisco, California. Its gxstrands unit commercializes CPTx's ssDNA manufacturing capabilities for research, gene-editing, allogeneic CAR-T, stem-cell-editing, and other biopharmaceutical applications. ([cptx.bio](https://cptx.bio/about-us/))
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:In vivo CAR-T and ssDNA genetic medicines
SIZE & FINANCIALS
Employees:1-50
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$29M disclosed financing; additional non-dilutive grant funding undisclosed
Investors:BlueYard Capital, SPRIND — German Federal Agency for Disruptive Innovation, Marius Nacht Group, Andrej Henkler / Leblon Capital, Bayern Kapital, Stefan Oschmann, Industry veterans and other private investors; complete syndicate not publicly disclosed
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical in vivo CAR-T platform
Modalities:Single-stranded DNA, Non-viral gene delivery, Targeted lipid nanoparticles, In vivo CAR-T, DNA nanostructures and DNA origami, Episomal DNA vectors, Multigene genetic payloads, Protein design and engineered biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:gxstrands — CPTx's ssDNA manufacturing/CDMO business and commercial platform. ([cptx.bio](https://cptx.bio/cptx-nanocell-therapeutics-project-awarded-eu-funding-for-innovative-in-vivo-car-t-therapy-with-immune-silent-single-stranded-dna/?utm_source=openai))
Key Partnerships:NanoCell Therapeutics — collaborative QUIET-CAR project using targeted LNPs and immune-quiet ssDNA for in vivo CAR-T therapy in oncology and autoimmune disease. ([cptx.bio](https://cptx.bio/cptx-nanocell-therapeutics-project-awarded-eu-funding-for-innovative-in-vivo-car-t-therapy-with-immune-silent-single-stranded-dna/?utm_source=openai)), European Union / Horizon Europe / Eureka Network — non-dilutive Eurostars support for the QUIET-CAR project. ([cptx.bio](https://cptx.bio/cptx-nanocell-therapeutics-project-awarded-eu-funding-for-innovative-in-vivo-car-t-therapy-with-immune-silent-single-stranded-dna/?utm_source=openai)), Technical University of Munich — scientific origin of the company's ssDNA engineering, DNA nanofabrication, and DNA-origami platform. ([cptx.bio](https://cptx.bio/about-us/)), Undisclosed biopharma partners — CPTx has referenced two partnership assets and strategic alliances but has not publicly named all counterparties. ([cptx.bio](https://cptx.bio/cptx-secures-30-million-to-advance-breakthrough-programmable-dna-nanofabrication-platform/))
COMPETITION
Position:Emerging — CPTx has differentiated ssDNA and DNA-nanofabrication capabilities but remains preclinical, without publicly disclosed human trials, approvals, or clinical efficacy data. The company operates in a rapidly consolidating in vivo CAR-T market where several competitors have entered the clinic or been acquired by major pharmaceutical companies. ([cptx.bio](https://cptx.bio/cptx-appoints-edward-rebar-as-chief-scientific-officer/))
Competitors:Capstan Therapeutics / AbbVie — non-viral LNP-based in vivo CAR-T; lead CD19 program CPTX2309 entered Phase 1 before AbbVie's acquisition. ([synapse-patsnap-com.sutd.idm.oclc.org](https://synapse-patsnap-com.sutd.idm.oclc.org/drug/d5f6c19cd32b4dc4b3f7d03dc4702fb1?utm_source=openai)), Kelonia Therapeutics / Eli Lilly — targeted lentiviral in vivo CAR-T platform; acquired by Lilly in 2026. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo?utm_source=openai)), Interius BioTherapeutics / Gilead Sciences — targeted lentiviral in vivo CAR-T platform; acquired by Gilead in 2025. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo?utm_source=openai)), EsoBiotec / AstraZeneca — in vivo CAR-T platform using non-CPTx delivery technology; acquired by AstraZeneca in 2025. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo?utm_source=openai)), Umoja Biopharma — VivoVec targeted viral-vector in vivo CAR-T platform. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Targeted_lentiviral_delivery_for_in_vivo_CAR_T-cell_generation?utm_source=openai)), Legend Biotech — LVIVO-TaVec100 dual CD19/CD20 in vivo CAR-T program. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC13169547/?utm_source=openai)), Myeloid Therapeutics — non-viral in vivo immune-cell engineering programs using LNP-based approaches. ([the-innovation.org](https://www.the-innovation.org/data/article/drugdiscovery/preview/pdf/TIDD-2026-0018.pdf?utm_source=openai)), Orna Therapeutics / Eli Lilly — circular-RNA-based in vivo cell-engineering platform and strategic competitor in the broader in vivo CAR-T field. ([asgct.org](https://www.asgct.org/uploads/files/general/Landscape-Report-2026-Q1.pdf?utm_source=openai))
LEADERSHIP
Key Executives:
Hendrik Dietz - CEO & Founder
Edward Rebar, PhD - Chief Scientific Officer
Grant Boldt, PhD - Chief Operating Officer
David Maier - Chief Business Officer
Stefan Oschmann - Chairman of the Board
Scientific Founders:Hendrik Dietz — founder and scientific originator of CPTx's ssDNA programming and DNA-nanofabrication platform. ([cptx.bio](https://cptx.bio/about-us/))
Board Members:Stefan Oschmann — Chairman of the Board. ([cptx.bio](https://cptx.bio/about-us/))
LINKS
Website:cptx.bio
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CPTx. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.